Clinical trial
Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating…
NCT00025480 · Abramson Cancer Center at Penn Medicine, Other · Completed
Key facts
| NCT number | NCT00025480 |
|---|---|
| Title | Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer |
| Official title | A Phase I Trial of Farnesyltransferase Inhibitor, R115777 (NSC # 702818) and Radiotherapy in Patients With Non-Small Cell Lung Cancer |
| Lead sponsor | Abramson Cancer Center at Penn Medicine, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug, Radiation |
| Interventions | carboplatin, paclitaxel, tipifarnib, radiation therapy |
| Enrollment | 12 |
| Start date | Aug 1, 2001 |
| First posted | Jan 27, 2003 |
| Last update posted | Mar 13, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: